WAVE Life Sciences Ltd. (NASDAQ:WVE) has been assigned an average broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $42.00 for the company and are expecting that the company will post ($0.69) EPS for the current quarter, according to Zacks. Zacks has also given WAVE Life Sciences an industry rank of 100 out of 265 based on the ratings given to related companies.
Several research firms recently weighed in on WVE. Leerink Swann reiterated an “outperform” rating and set a $45.00 target price on shares of WAVE Life Sciences in a research report on Thursday, November 10th. JMP Securities reiterated a “buy” rating on shares of WAVE Life Sciences in a research report on Thursday, November 10th. Jefferies Group LLC lifted their target price on WAVE Life Sciences from $28.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, November 14th. Zacks Investment Research downgraded WAVE Life Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, November 15th. Finally, HC Wainwright began coverage on WAVE Life Sciences in a research report on Wednesday. They set a “buy” rating and a $41.00 target price on the stock.
This piece was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was illegally stolen and reposted in violation of international copyright and trademark laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/02/17/wave-life-sciences-ltd-wve-given-consensus-recommendation-of-strong-buy-by-brokerages.html.
Institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN bought a new position in WAVE Life Sciences during the third quarter valued at $136,000. Strs Ohio bought a new position in WAVE Life Sciences during the third quarter valued at $194,000. Lesa Sroufe & Co bought a new position in WAVE Life Sciences during the third quarter valued at $209,000. Deschutes Portfolio Strategy LLC bought a new position in WAVE Life Sciences during the third quarter valued at $334,000. Finally, Renaissance Technologies LLC bought a new position in WAVE Life Sciences during the fourth quarter valued at $403,000. Institutional investors own 59.83% of the company’s stock.
WAVE Life Sciences (NASDAQ:WVE) opened at 30.00 on Tuesday. The stock has a 50 day moving average price of $28.30 and a 200-day moving average price of $29.07. WAVE Life Sciences has a 12-month low of $11.99 and a 12-month high of $40.15. The stock’s market capitalization is $704.25 million.
WAVE Life Sciences Company Profile
WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.